Europe responding to gene therapy challenge, but picture remains fragmented

20 May 2019 - Germany, Italy and England using outcomes-based deals. ...

Read more →

NHS chief hails SMA drug deal – and was that a swipe at Vertex?

15 May 2019 - Children in England with the rare muscle wasting disease spinal muscular atrophy will get access to ...

Read more →

CMS issues new guidance addressing spread pricing in Medicaid, ensures Pharmacy Benefit Managers are not up-charging taxpayers

15 May 2019 - Agency issues guidance for Medicaid Managed Care and CHIP health plans that clarifies how current regulations require ...

Read more →

AbbVie announces US FDA approval of Venclexta (venetoclax) as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukaemia patients

15 May 2019 - FDA reviewed the submission under the real-time oncology review pilot program. ...

Read more →

Lipocine announces Tlando NDA PDUFA action date of 9 November 2019

14 May 2019 - Lipocine today announced that the U.S.FDA has accepted its new drug application for Tlando as testosterone ...

Read more →

Trump bucks his own party again. This time, it's on importing drugs from Canada.

15 May 2019 - President Donald Trump's latest plan to lower drug prices is drawing concerns from Health Secretary Alex ...

Read more →

NICE recommends first ever treatment for children with rare muscle wasting condition

15 May 2019 - Children with the rare genetic disorder spinal muscular atrophy can now be treated with nusinersen after NICE ...

Read more →

Cystic fibrosis drug campaign makes no progress in year

10 May 2019 - It is a year on from the delivery of more than 1,000 letters to Downing Street, ...

Read more →

Homology Medicines announces FDA fast track designation for HMI-102 gene therapy development candidate for adults with PKU

14 May 2019 - Company provides details of pheNIX, the first gene therapy trial for PKU, and remains on track to ...

Read more →

FDA approves Bavencio (avelumab) plus axitinib combination for patients with advanced renal cell carcinoma

14 May 2019 - Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended ...

Read more →

A new study sparks a war of words over the drug industry’s commitment to research

14 May 2019 - The pharmaceutical industry spends about $1 in $5 of its revenues on research and development. ...

Read more →

PHARMAC publishes list of applications to be considered by PTAC later this month

14 May 2019 - The list includes a number of medicines for patients with breast cancer. ...

Read more →

Analysis of sponsor hearings on PBAC decision making

14 May 2019 - Original research conducted by Melinda Flowers, Sean Lybrand and myself has been published on-line in the ...

Read more →

Cracks in the system: without a national Pharmacare strategy, who is left behind?

14 May 2019 - Lack of public or private insurance, incomplete drug coverage or just plain sky-high prices for drugs that ...

Read more →

Don’t buy pharma’s lies

14 May 2019 - As universal pharmacare gets closer to reality for Canada, drug companies are ramping up their false ...

Read more →

Canadian health care stuck in the ’60s, expert says

14 May 2019 - When Patty De Guia lost her leg to cancer months after giving birth to her third ...

Read more →